HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells
γδT cells have potent effects on hematological malignancies, and their functions can be regulated by anti-tumor agents. Histone deacetylase inhibitors (HDACis) not only have antileukemic activity on leukemia but also affect immune cells during therapeutic application. In this in vitro study, we show...
Main Authors: | Ying He, Lin Xu, Jingjing Feng, Kangni Wu, Yanmin Zhao, He Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770520301200 |
Similar Items
-
Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2′-deoxymethylene nucleosides
by: Khairia M. Youssef, et al.
Published: (2015-12-01) -
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
by: Nageatte Ibrahim, et al.
Published: (2016-11-01) -
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells
by: Laura Urwanisch, et al.
Published: (2023-02-01) -
Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells
by: Yingjun Li, et al.
Published: (2022-07-01) -
HDAC4 Regulates the Proliferation, Differentiation and Apoptosis of Chicken Skeletal Muscle Satellite Cells
by: Jing Zhao, et al.
Published: (2020-01-01)